Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity (2016 - 2025)

Monopar Therapeutics has disclosed Liabilities and Shareholders Equity across 10 years of filings, most recently posting $140.7 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $140.7 million, up 133.4% year-over-year; the trailing twelve-month figure through Dec 2025 was $393.9 million (up 377.69% YoY), and the FY2025 annual result was $140.7 million, up 133.4% from the prior year.
• Liabilities and Shareholders Equity came in at $140.7 million for Q4 2025 at Monopar Therapeutics, down from $144.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $144.2 million in Q3 2025 to a low of $6.1 million in Q3 2024.
• The 5-year median for Liabilities and Shareholders Equity is $17.4 million (2022), against an average of $33.5 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 44.47% in 2023 and soared 2275.71% in 2025, its largest moves.
• Monopar Therapeutics' Liabilities and Shareholders Equity stood at $20.5 million in 2021, then tumbled by 35.55% to $13.2 million in 2022, then sank by 44.47% to $7.3 million in 2023, then soared by 720.83% to $60.3 million in 2024, then surged by 133.4% to $140.7 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $140.7 million (Q4 2025), $144.2 million (Q3 2025), and $53.9 million (Q2 2025), per Business Quant data.